
Medtronic PLC
NYSE:MDT

MDT's latest stock split occurred on Sep 27, 1999
The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.
The adjusted shares began trading on Sep 27, 1999. This was MDT's 8th stock split, following the previous one in Sep 15, 1997.
Medtronic PLC
Glance View
In the intricate world of medical technology, Medtronic PLC stands tall as one of the foremost innovators transforming the landscape of healthcare. Founded in 1949 as a humble medical supply repair shop in Minnesota, Medtronic has grown into a global titan, driven by the enduring mission to alleviate pain, restore health, and extend life. The company's breadth is vast, touching nearly every aspect of patient care, from advanced robotic-assisted surgery systems to sophisticated insulin pumps. At its core, Medtronic thrives on relentless research and development, continually bridging the gap between cutting-edge technology and practical medical solutions. By forging deep alliances with healthcare providers and systems around the globe, the company ensures its innovations are not only groundbreaking but also widely accessible. The company's financial engine purrs to life primarily through the development and sale of medical devices across four major segments: Cardiac and Vascular Group, Minimally Invasive Therapies, Restorative Therapies Group, and Diabetes Group. Each unit meticulously focuses on innovating and providing solutions relevant to its field, ensuring a diversified portfolio with robust pipelines. For instance, within the Cardiac and Vascular Group, Medtronic supplies life-saving products like pacemakers and stents while also exploring breakthrough therapies such as transcatheter heart valves. By capitalizing on a global presence, the company strategically taps into both mature markets in North America and Europe and emerging markets across Asia and Latin America, thereby driving substantial revenue streams. Through this multifaceted operational framework, Medtronic not only sustains its market dominance but also reinvests in the future of medical technology, symbolizing a perpetual cycle of growth and innovation.
